Celcuity (NASDAQ:CELC) Earns “Buy” Rating from Craig Hallum

Celcuity (NASDAQ:CELC)‘s stock had its “buy” rating restated by analysts at Craig Hallum in a research note issued to investors on Thursday, Benzinga reports. They currently have a $27.00 price target on the stock, up from their previous price target of $25.00. Craig Hallum’s price target would indicate a potential upside of 51.09% from the company’s current price.

A number of other brokerages have also commented on CELC. Needham & Company LLC reissued a “buy” rating and issued a $24.00 price objective on shares of Celcuity in a research report on Thursday. Stifel Nicolaus started coverage on shares of Celcuity in a research note on Thursday, February 22nd. They set a “buy” rating and a $40.00 price objective for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $27.00 target price on shares of Celcuity in a research report on Thursday.

Celcuity Stock Up 3.7 %

Shares of CELC traded up $0.64 during midday trading on Thursday, hitting $17.87. The stock had a trading volume of 75,456 shares, compared to its average volume of 215,981. The firm has a market cap of $544.14 million, a price-to-earnings ratio of -6.74 and a beta of 0.87. The company has a 50 day simple moving average of $17.99 and a two-hundred day simple moving average of $15.56. Celcuity has a twelve month low of $8.39 and a twelve month high of $22.19. The company has a debt-to-equity ratio of 0.26, a current ratio of 13.43 and a quick ratio of 13.43.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Wednesday, March 27th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.06. On average, analysts anticipate that Celcuity will post -2.93 EPS for the current year.

Institutional Trading of Celcuity

A number of large investors have recently added to or reduced their stakes in CELC. BNP Paribas Financial Markets increased its stake in shares of Celcuity by 78.5% during the 1st quarter. BNP Paribas Financial Markets now owns 8,937 shares of the company’s stock worth $193,000 after purchasing an additional 3,930 shares during the last quarter. Pale Fire Capital SE grew its holdings in Celcuity by 38.4% during the fourth quarter. Pale Fire Capital SE now owns 14,409 shares of the company’s stock worth $210,000 after purchasing an additional 4,000 shares during the period. Vanguard Group Inc. increased its position in Celcuity by 1.0% during the first quarter. Vanguard Group Inc. now owns 828,597 shares of the company’s stock worth $17,898,000 after buying an additional 7,821 shares during the last quarter. SG Americas Securities LLC bought a new stake in Celcuity in the fourth quarter valued at approximately $139,000. Finally, Trust Point Inc. acquired a new stake in shares of Celcuity in the fourth quarter valued at approximately $297,000. Institutional investors and hedge funds own 63.33% of the company’s stock.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.